Speaker illustration

Professor Pasquale Pignatelli Spinazzola

Sapienza University of Rome, Rome (Italy)

Prof. Pignatelli works as full professor of internal medicinein the First internal Medice Clinic. Moreover, he is in charge as Dean of The Antithrombotic Center (AVK and NOACs center) , First Clinic, Sapienza University of Rome, coordinating a staff composed by physicians and nurses involved in both assistance and research in the field of atherothrombosis. This permits Him to access a large umber of Patients starting and monitoring anticoagulant therapies with both anti vitamin K antagonists and the new direct oral anticoagulants. All these results in a large number of publication in the fiend of anticoagulations in patients affected by atherothrombotic diseases and in particular atrial fibrillation. This last Issue represents the main interest of Dr Pignatelli resulting in more than 40 publications in the specific topic. Didactics data: He is the Dean of the Sapinenza University PhD school in Cardio Thoracic phytopathology and teaches in the Sapienza Medical school.

Proprotein convertase subtilisin/kexin 9 (PCSK9) and lipopolysaccharide (LPS) in patients with atrial fibrillation. A biomarker post-hoc analysis from the ATHERO-AF cohort.

Event: ESC Congress 2019

Topic: Inflammation and Immunity

Session: Coronary artery disease inflammation


digoxin and platelet activation in atrial fibrillation patients.

Event: EHRA 2018

Topic: Mechanisms for Heart Failure and Cardiac Complications in Atrial Fibrillation

Session: Basic Science


Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and risk of cardiovascular events in atrial fibrillation

Event: ESC Congress 2017

Topic: Thrombosis and coagulation

Session: Coronary artery disease: from bench to bedside


Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding.

Event: ESC Congress 2016

Topic: Atrial fibrillation (AF)

Session: Anticoagulation in atrial fibrillation III


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb